Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ascendis Pharma A (ASND) Enterprise Value: 2012-2025

Historic Enterprise Value for Ascendis Pharma A (ASND) over the last 12 years, with Sep 2025 value amounting to $11.4 billion.

  • Ascendis Pharma A's Enterprise Value rose 44.87% to $11.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.7 billion, marking a year-over-year increase of 42.35%. This contributed to the annual value of $7.3 billion for FY2024, which is 7.07% up from last year.
  • As of Q3 2025, Ascendis Pharma A's Enterprise Value stood at $11.4 billion, which was up 15.69% from $9.9 billion recorded in Q2 2025.
  • Over the past 5 years, Ascendis Pharma A's Enterprise Value peaked at $11.4 billion during Q3 2025, and registered a low of $4.2 billion during Q2 2022.
  • In the last 3 years, Ascendis Pharma A's Enterprise Value had a median value of $7.7 billion in 2024 and averaged $7.6 billion.
  • Its Enterprise Value has fluctuated over the past 5 years, first slumped by 35.59% in 2022, then surged by 65.15% in 2024.
  • Over the past 5 years, Ascendis Pharma A's Enterprise Value (Quarterly) stood at $6.5 billion in 2021, then fell by 3.82% to $6.2 billion in 2022, then climbed by 9.94% to $6.8 billion in 2023, then increased by 7.19% to $7.3 billion in 2024, then soared by 44.87% to $11.4 billion in 2025.
  • Its Enterprise Value stands at $11.4 billion for Q3 2025, versus $9.9 billion for Q2 2025 and $8.9 billion for Q1 2025.